Ezallor Sprinkle is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 1 US drug patent filed in 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 12, 2036. Details of Ezallor Sprinkle's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10413543 | Stable multiparticulate pharmaceutical composition of rosuvastatin |
Feb, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ezallor Sprinkle's patents.
Latest Legal Activities on Ezallor Sprinkle's Patents
Given below is the list of recent legal activities going on the following patents of Ezallor Sprinkle.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Mar, 2023 | US10413543 |
| Recordation of Patent Grant Mailed | 17 Sep, 2019 | US10413543 |
| Patent Issue Date Used in PTA Calculation | 17 Sep, 2019 | US10413543 |
| Email Notification | 29 Aug, 2019 | US10413543 |
| Issue Notification Mailed | 28 Aug, 2019 | US10413543 |
| Application Is Considered Ready for Issue | 05 Aug, 2019 | US10413543 |
| Dispatch to FDC | 05 Aug, 2019 | US10413543 |
| Issue Fee Payment Verified | 30 Jul, 2019 | US10413543 |
| Issue Fee Payment Received | 30 Jul, 2019 | US10413543 |
| Supplemental Papers - Oath or Declaration | 29 Jul, 2019 | US10413543 |
US patents provide insights into the exclusivity only within the United States, but Ezallor Sprinkle is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ezallor Sprinkle's family patents as well as insights into ongoing legal events on those patents.
Ezallor Sprinkle's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Ezallor Sprinkle's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 12, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ezallor Sprinkle Generics:
Rosuvastatin Calcium is the generic name for the brand Ezallor Sprinkle. 27 different companies have already filed for the generic of Ezallor Sprinkle, with Accord Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ezallor Sprinkle's generic
About Ezallor Sprinkle
Ezallor Sprinkle is a drug owned by Sun Pharmaceutical Industries Ltd. Ezallor Sprinkle uses Rosuvastatin Calcium as an active ingredient. Ezallor Sprinkle was launched by Sun Pharm in 2018.
Can you believe Ezallor Sprinkle received compensation for the extended wait time during the regulatory approval process?
A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent. The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.
Market Authorisation Date:
Ezallor Sprinkle was approved by FDA for market use on 18 December, 2018.
Active Ingredient:
Ezallor Sprinkle uses Rosuvastatin Calcium as the active ingredient. Check out other Drugs and Companies using Rosuvastatin Calcium ingredient
Dosage:
Ezallor Sprinkle is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 40MG BASE | CAPSULE | Discontinued | ORAL |
| EQ 5MG BASE | CAPSULE | Discontinued | ORAL |
| EQ 20MG BASE | CAPSULE | Discontinued | ORAL |
| EQ 10MG BASE | CAPSULE | Discontinued | ORAL |